CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy

Authors
Yan Y. 1 , Adjei A.A. 1, 3 , Mansfield A.S. 1 , Markovic S.N. 1 , Dronca R.S. 1 , Cao S. 2 , Liu X. 2 , Harrington S.M. 2 , Bindeman W.E. 2 , Dong H. 2, 7 , Jang J.S. 4 , Jen J. 4 , Li Y. 5 , Chanana P. 5 , Park S.S. 6
Journal
JCI Insight
Issue number
8
Language
English
State
Published
DOI
10.1172/JCI.INSIGHT.97828
Volume
3
Year
2018
Organizations
  • 1 Division of Medical Oncology
  • 2 Mayo Clinic Cancer Center Early Therapeutic Program
  • 3 Department of Urology
  • 4 Department of Immunology|Mayo Clinic
  • 5 Mayo Clinic Center of Individualized Medicine
  • 6 Department of Biomedical Statistics and Informatics
  • 7 Department of Radiation Oncology
Cite
ГОСТ MLA RIS BibTex
Share

Other records

NT-PROBNP (N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE)-GUIDED THERAPY IN ACUTE DECOMPENSATED HEART FAILURE PRIMA II RANDOMIZED CONTROLLED TRIAL (CAN NT-PROBNP-GUIDED THERAPY DURING HOSPITAL ADMISSION FOR ACUTE DECOMPENSATED HEART FAILURE REDUCE MORTALITY AND READMISSIONS?)

Article
Stienen S., Salah K., Tijssen J.G.P., Pinto Y.M., Kok W.E., Moons A.H., Bakx A.L., Van Pol P., Kortz R.A.M., Ferreira J.P., Marques I., Schroeder-Tanka J.M., Keijer J.T., Bayés-Genis A.
Circulation. Vol. 137. 2018. P.. 1671-1683